Compare Medpace Holdings Inc (MEDP) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs VF Corp — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while VF Corp trades at $14.98 (market cap $5.71B). The key difference: Medpace Holdings Inc is far larger — about 2.9× VF Corp's market cap, and VF Corp pays a 2.48% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and VF Corp for 64 Days on average.
| MEDP | VFC | |
|---|---|---|
Market Cap | $16.82B | $5.71B |
Volume | 223,093 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $21.55 |
52-Week Low | $393.42 | $12.62 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | $16.44B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
VFC trades at $14.38, down 0.48% with a bullish technical signal from moving averages. The company shows mixed fundamentals with revenue declining from $11.8B in 2022 to $9.5B in 2025, while profitability remains challenged with negative net income of -$189.72M. Recent earnings show volatility with one beat and two misses in the last four quarters. The stock trades at attractive valuation multiples with P/E of 21.06 and P/S of 0.61, below industry averages.
VFC presents a turnaround opportunity with discounted valuation and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and ongoing debt reduction challenges. Analyst consensus leans neutral with 52% hold rating and $18.33 price target suggesting 27% upside potential, though recent dividend cuts and brand-specific headwinds require careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
